HRTX vs MCK vs CAH vs PACB

For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.

2% revenue growth year-over-year, versus -1. 9% for Cardinal Health, Inc. (CAH). Cardinal Health, Inc. (CAH) offers the better valuation at 28. 7x trailing P/E (17. 1x forward), making it the more compelling value choice. Analysts rate Heron Therapeutics, Inc. (HRTX) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Cardinal Health, Inc.

(CAH) is the cheapest at 28. 7x versus McKesson Corporation at 29. 2x. On forward P/E, McKesson Corporation is actually cheaper at 16. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to -93. 4% for Pacific Biosciences of California, Inc. (PACB). Over 10 years, the gap is even starker: MCK returned +339. 0% versus HRTX's -93. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at -0.

02β versus Pacific Biosciences of California, Inc. 's 2. 41β — meaning PACB is approximately -14773% more volatile than MCK relative to the S&P 500. On balance sheet safety, Heron Therapeutics, Inc. (HRTX) carries a lower debt/equity ratio of 10% versus 142% for Pacific Biosciences of California, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.

2% versus -1. 9% for Cardinal Health, Inc. (CAH). On earnings-per-share growth, the picture is similar: Cardinal Health, Inc. grew EPS 87. 0% year-over-year, compared to -70. 1% for Pacific Biosciences of California, Inc.. Over a 3-year CAGR, HRTX leads at 12. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

McKesson Corporation (MCK) is the more profitable company, earning 0.

9% net margin versus -341. 5% for Pacific Biosciences of California, Inc. — meaning it keeps 0. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCK leads at 1. 2% versus -348. 5% for PACB. At the gross margin level — before operating expenses — HRTX leads at 73. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, McKesson Corporation (MCK) trades at 16.

7x forward P/E versus 17. 1x for Cardinal Health, Inc. — 0. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HRTX: 437. 9% to $6. 67.

In this comparison, CAH (1.

1% yield), MCK (0. 4% yield) pay a dividend. HRTX, PACB do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Cardinal Health, Inc.

(CAH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 01), 1. 1% yield, +158. 8% 10Y return). Pacific Biosciences of California, Inc. (PACB) carries a higher beta of 2. 41 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CAH: +158. 8%, PACB: -84. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: HRTX is a small-cap quality compounder stock; MCK is a mid-cap high-growth stock; CAH is a mid-cap quality compounder stock; PACB is a small-cap quality compounder stock. CAH pays a dividend while HRTX, MCK, PACB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.